Online inquiry

IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14809MR)

This product GTTS-WQ14809MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD70 gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001252.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 970
UniProt ID P32970
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14809MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12248MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ13115MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ12552MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ8461MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ4615MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ10003MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ5326MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ1599MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACE-536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW